Recursion Pharmaceuticals, Inc.

As of June 30, 2026, Recursion Pharmaceuticals, Inc. Class A carries a market capitalization of 33.65B, placing it among publicly traded companies globally. Its enterprise value stands at 25.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Recursion Pharmaceuticals, Inc. Class A's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Recursion Pharmaceuticals, Inc. Class A has 534.12M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 34.02, and the price-to-book ratio stands at 2.10.

These figures are as of June 30, 2026. The EV/Sales ratio of 26.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 25.28B versus a market cap of 33.65B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Recursion Pharmaceuticals, Inc. Class A maintains a current ratio of 5.03, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.28, indicating elevated leverage, while an interest coverage ratio of -314.41 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Recursion Pharmaceuticals, Inc. Class A posted a negative return on equity (ROE) of -56.58, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -41.26, reflecting losses generated across the asset base. The company generates approximately 1.45M in revenue per employee across its workforce of 650.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Recursion Pharmaceuticals, Inc. Class A recorded an income tax benefit of -80.05M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -9.15B and -9.07B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, Recursion Pharmaceuticals, Inc. Class A's stock has declined approximately 39.13% over the past 52 weeks. The 50-day moving average sits at 63.46, while the 200-day moving average is 74.68.

Over the twelve months ended June 30, 2026, Recursion Pharmaceuticals, Inc. Class A generated 942.38M in revenue and converted that into -9.07B in net income, yielding earnings per share of -17.82. EBITDA reached -8.14B, while operating income came in at -9.50B.

As of June 30, 2026, Recursion Pharmaceuticals, Inc. Class A holds 9.53B in cash and equivalents against 1.16B in total debt, resulting in a net debt position of -9.29B. Total book value stands at 15.99B, with working capital of 8.45B providing operational flexibility.

Recursion Pharmaceuticals, Inc. Class A produced -6.12B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -66.11M in capital expenditures, free cash flow totaled -6.19B - equivalent to -12.16 per share.

Over the twelve months ended June 30, 2026, Recursion Pharmaceuticals, Inc. Class A posted a gross margin of 1.84, reflecting its pricing power and cost economics. The operating margin of -1,008.58 and net profit margin of -962.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -19.31: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -19.66, meaning Recursion Pharmaceuticals, Inc. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Recursion Pharmaceuticals, Inc. Class A has an Altman Z-Score of -1.86, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.